Skip to main content
Potentially dodgy stem cell trials threaten valid studies
6/11/2019

The FDA has been cracking down on companies and clinics that market unapproved, unproven stem cell therapies, but some of the organizations' trials remain listed on clinicaltrials.gov, which critics say gives the firms undeserved credibility. Critics also say that charging participants, as some stem cell studies do, is unethical, and trials run by unapproved sellers threaten participation in valid studies that comply with federal regulations.

Full Story: